ALSUntangled #71: Nuedexta. Amyotroph Lateral Scler Frontotemporal Degener 2024 Feb;25(1-2):218-222
Date
07/26/2023Pubmed ID
37493197DOI
10.1080/21678421.2023.2239292Scopus ID
2-s2.0-85165715762 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Nuedexta is a combination of dextromethorphan hydrobromide and quinidine sulfate and was approved by the Food and Drug Administration (FDA) in 2010 to treat pseudobulbar affect (PBA). There have since been anecdotal case reports of bulbar function improvements after Nuedexta treatment. Here, we review the off-label use of Nuedexta for improving bulbar function in people with ALS. Nuedexta has plausible mechanisms for protecting brain stem motor neurons via its effects on S1R and glutamate excitotoxicity. Recent clinical trials support that Nuedexta can improve bulbar function in PALS, with or without PBA. Nuedexta causes mild to moderate side effects. Based on this information, we support considering Nuedexta treatment for bulbar dysfunction in ALS patients with or without PBA.
Author List
Sun Y, Benatar M, Mascías Cadavid J, Ennist D, Wicks P, Staats K, Beauchamp M, Jhooty S, Pattee G, Brown A, Bertorini T, Barkhaus P, Bromberg M, Carter G, Bedlack R, Li XAuthor
Paul E. Barkhaus MD Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Amyotrophic Lateral SclerosisDextromethorphan
Drug Combinations
Humans
Quinidine
